Clinical observation of adjuvant therapy of Yupingfeng particles in bronchial asthma children with recurrent respiratory tract infection and its influence on humoral immunity function / 中国生化药物杂志

ABSTRACT

Objective To observe the curative efficacy of adjuvant therapy of Yupingfeng particles in bronchial asthma children with recurrent respiratory tract infection (RRTI) and its influence on humoral immunity function. Methods 98 patients of bronchial asthma children with RRTI meeting the inclusion criteria were collected as observation objects. Retrospectively analyzing their clinical materials, those patients were divided into the control group (n=42) and the observation group (n=56) according to therapeutic schemes. The control group was given conventional treatments. Besides that, the observation group was given adjuvant therapy of Yupingfeng particles. Then, curative efficacy, humoral immunity related indices and adverse reactions were compared between the two groups. Results As to curative efficacy related indices after six-month follow-up, the observation group had less times of respiratory tract infection [(2.53±0.94) vs.(4.06±1.38)times], shorter asthma wheeling time and shorter time of using antibiotics [(0.67±0.12) vs. (1.74±0.52) d, (8.29±2.15) vs. (15.37±3.42) d] with all statistical differences (all P<0.05). After treatment, in comparison with the control group, levels of humoral immunity indices of serum IgA, IgG were statistically higher in the observation group [(0.93±0.17) vs. (0.49±0.11) g/L; (7.52±0.78) vs. (6.35±0.70) g/L, both P<0.05]. During the treatment, there's no case of severe adverse reactions. And the incidences of adverse reactions in the control group and the observation group were statistically same (4.8% vs. 8.9%). Conclusion Adjuvant therapy of Yupingfeng particles has well curative efficacy in bronchial asthma children with RRTI. And it can reduce occurrence of respiratory tract infection and promote humoral immunity function with minor adverse reactions.